Question special
Faculty Member

In the amplify extend study with apixaban, the control was placebo. While chosing aspirin lifts the efficacy bar, the safety parameters of aspirin are arguably different than placebo.

Why did you select aspirin over placebo?

What does the difference say about the apparent differences in bleeding risk of apixaban and rivaroxaban at current doses?